Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

U. Popat, C. Hosing, R. M. Saliba, P. Anderlini, K. van Besien, D. Przepiorka, I. F. Khouri, J. Gajewski, D. Claxton, S. Giralt, M. Rodriguez, J. Romaguera, F. Hagemeister, C. Ha, J. Cox, F. Cabanillas, B. S. Andersson, R. E. Champlin

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34% (95% CI 27-42) and 29% (95% CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.

Original languageEnglish (US)
Pages (from-to)1015-1023
Number of pages9
JournalBone Marrow Transplantation
Volume33
Issue number10
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Disease Progression
Drug Therapy
Transplantation
Recurrence
Salvage Therapy
Induction Chemotherapy
Autologous Transplantation
Stem Cell Transplantation
Treatment Failure
Disease-Free Survival
Survival Rate

Keywords

  • Autologous transplantation
  • Hodgkin's lymphoma
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. / Popat, U.; Hosing, C.; Saliba, R. M.; Anderlini, P.; van Besien, K.; Przepiorka, D.; Khouri, I. F.; Gajewski, J.; Claxton, D.; Giralt, S.; Rodriguez, M.; Romaguera, J.; Hagemeister, F.; Ha, C.; Cox, J.; Cabanillas, F.; Andersson, B. S.; Champlin, R. E.

In: Bone Marrow Transplantation, Vol. 33, No. 10, 05.2004, p. 1015-1023.

Research output: Contribution to journalArticle

Popat, U, Hosing, C, Saliba, RM, Anderlini, P, van Besien, K, Przepiorka, D, Khouri, IF, Gajewski, J, Claxton, D, Giralt, S, Rodriguez, M, Romaguera, J, Hagemeister, F, Ha, C, Cox, J, Cabanillas, F, Andersson, BS & Champlin, RE 2004, 'Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma', Bone Marrow Transplantation, vol. 33, no. 10, pp. 1015-1023. https://doi.org/10.1038/sj.bmt.1704483
Popat, U. ; Hosing, C. ; Saliba, R. M. ; Anderlini, P. ; van Besien, K. ; Przepiorka, D. ; Khouri, I. F. ; Gajewski, J. ; Claxton, D. ; Giralt, S. ; Rodriguez, M. ; Romaguera, J. ; Hagemeister, F. ; Ha, C. ; Cox, J. ; Cabanillas, F. ; Andersson, B. S. ; Champlin, R. E. / Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 10. pp. 1015-1023.
@article{a475562f440e4303963763c550bb2bca,
title = "Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma",
abstract = "Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34{\%} (95{\%} CI 27-42) and 29{\%} (95{\%} CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.",
keywords = "Autologous transplantation, Hodgkin's lymphoma, Prognostic factors",
author = "U. Popat and C. Hosing and Saliba, {R. M.} and P. Anderlini and {van Besien}, K. and D. Przepiorka and Khouri, {I. F.} and J. Gajewski and D. Claxton and S. Giralt and M. Rodriguez and J. Romaguera and F. Hagemeister and C. Ha and J. Cox and F. Cabanillas and Andersson, {B. S.} and Champlin, {R. E.}",
year = "2004",
month = "5",
doi = "10.1038/sj.bmt.1704483",
language = "English (US)",
volume = "33",
pages = "1015--1023",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

AU - Popat, U.

AU - Hosing, C.

AU - Saliba, R. M.

AU - Anderlini, P.

AU - van Besien, K.

AU - Przepiorka, D.

AU - Khouri, I. F.

AU - Gajewski, J.

AU - Claxton, D.

AU - Giralt, S.

AU - Rodriguez, M.

AU - Romaguera, J.

AU - Hagemeister, F.

AU - Ha, C.

AU - Cox, J.

AU - Cabanillas, F.

AU - Andersson, B. S.

AU - Champlin, R. E.

PY - 2004/5

Y1 - 2004/5

N2 - Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34% (95% CI 27-42) and 29% (95% CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.

AB - Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation. At the time of transplantation, 82 patients were in first relapse or second remission, 46 patients were refractory to the primary induction chemotherapy, and 56 patients were beyond first relapse or second remission. In 64 patients, the disease had proved refractory to the chemotherapy regimen administered immediately prior to transplantation. The median follow-up of patients who were alive and free of disease at the time of this report was 8.9 years (range, 0.1-19.0 years). At 10 years, the overall and disease-free survival rates were 34% (95% CI 27-42) and 29% (95% CI 22-36) respectively. The major cause of treatment failure was disease relapse. Chemotherapy resistance prior to transplantation, advanced stage, and higher number of chemotherapy regimens administered prior to transplantation were adverse prognostic factors for disease progression. We conclude that autologous transplantation is an effective salvage treatment for recurrent HL.

KW - Autologous transplantation

KW - Hodgkin's lymphoma

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=2942536855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942536855&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704483

DO - 10.1038/sj.bmt.1704483

M3 - Article

C2 - 15048145

AN - SCOPUS:2942536855

VL - 33

SP - 1015

EP - 1023

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -